Meteospasmyl – a fixed combination of alverine citrate and simethicone in the treatment of digestive tract functional disorders

Czech version

Authors: M. Lukáš
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha
Published in: Gastroent Hepatol 2017; 71(5): 455-456
Category: Drug Profile
doi: https://doi.org/10.14735/amgh2017455

Sources

1. Juřica J, Kroupa R. Farmakoterapie dráždivého tračníku. Prakt Lékáren 2017; 13 (2): 52–59.

2. Lukáš M, Bultas J. Léčiva určena k terapii chorob trávicího traktu. In: Bultas J. Klinická farmakologie. V tisku.

3. Abysique A, Lucchini S, Orsoni P. Effects of alverine citrate on cat intestinal mechanoreceptors reponses to chemical and mechanical stimuli. Aliment Pharmacol Ther 1999; 13 (4): 561–566.

4. Bueno L, Beaufrand C, Theodorou V et al. Influence of simethicone and alverine on stress-induced alterations of colonic permeability and sensitivity in rats: beneficial effect of their association. J Pharm Pharmacol 2013; 65 (4): 567–573. doi: 10.1111/ jphp.12021.

5. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA et al. Effect of antispasmodic agents, alone or in combination, in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex 2012; 77 (2): 82–90. doi: 10.1016/j.rgmx.2012.04.002.

6. Ducrotte P, Grimaud JC, Dapoigny M et al. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract 2014; 68 (2): 245–254. doi: 10.1111/ijcp.12333.

7. Soto H, Pizarro M, Botello B et al. Cost effectiveness analysis of Alverine/Simethicone (Meteospasmyl^®) in the treatment of patients with IBS in Mexico. Value Health 2013; 16: Abstract PGI17.